Pediatric melanoma: Are recent advances in the management of adult melanoma relevant to the pediatric population

被引:42
作者
Gibbs, P [1 ]
Moore, A [1 ]
Robinson, W [1 ]
Walsh, P [1 ]
Golitz, L [1 ]
Gonzalez, R [1 ]
机构
[1] Univ Colorado, Ctr Canc, Denver, CO 80262 USA
关键词
melanoma; pediatric; therapy;
D O I
10.1097/00043426-200009000-00008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Although melanoma in childhood is a rare condition, there is evidence that it is increasing in frequency. As advances are being made in the understanding and therapy of adult melanoma, we need to consider the relevance of these advances to the pediatric population. Patients and Methods: We have reviewed our experience at the:University of Colorado Health Sciences Center with the clinical parameters, therapy, and outcomes of melanoma in 27 patients age 16 years or younger and contrasted these to the adult experience. Results: Most cases were diagnosed early with the median thickness of the primary melanoma being 0.75 mm. Six of seven patients who had lymph node metastases develop remain alive at a median follow-up of 62 months. Durable complete responses to a variety of therapies were seen in three of five patients with advanced disease outside the central nervous system. Our experience with sentinel node biopsy, adjuvant interferon, and new therapies for metastatic melanoma were also reviewed and appear to be relevant for younger patients. Conclusions: The behavior of melanoma in the pediatric population at our center is similar to that seen in adults. The integration of recent advances in the staging and therapy of melanoma in adults would be of benefit to children with this condition.
引用
收藏
页码:428 / 432
页数:5
相关论文
共 18 条
[1]  
Anderson C M, 1995, Oncology (Williston Park), V9, P1149
[2]  
[Anonymous], 1992, SURG ONCOLOGY CLIN
[3]   High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993 [J].
Atkins, MB ;
Lotze, MT ;
Dutcher, JP ;
Fisher, RI ;
Weiss, G ;
Margolin, K ;
Abrams, J ;
Sznol, M ;
Parkinson, D ;
Hawkins, M ;
Paradise, C ;
Kunkel, L ;
Rosenberg, SA .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2105-2116
[4]   Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients [J].
Gershenwald, JE ;
Thompson, W ;
Mansfield, PF ;
Lee, JE ;
Colome, MI ;
Tseng, CH ;
Lee, JJ ;
Balch, CM ;
Reintgen, DS ;
Ross, MI .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :976-983
[5]  
Karakousis CP, 1998, SEMIN SURG ONCOL, V14, P291, DOI 10.1002/(SICI)1098-2388(199806)14:4<291::AID-SSU5>3.0.CO
[6]  
2-Y
[7]   Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684 [J].
Kirkwood, JM ;
Strawderman, MH ;
Ernstoff, MS ;
Smith, TJ ;
Borden, EC ;
Blum, RH .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (01) :7-17
[8]  
KIRKWOOD JM, 1999, P AM SOC CLIN ONCOL, V35, pA2072
[9]   Large congenital melanocytic nevi and the risk for the development of malignant melanoma - A prospective study [J].
Marghoob, AA ;
Schoenbach, SP ;
Kopf, AW ;
Orlow, SJ ;
Nossa, R ;
Bart, RS .
ARCHIVES OF DERMATOLOGY, 1996, 132 (02) :170-175
[10]  
MEYERS ML, 1997, CUTANEOUS MELANOMA, P325